← All trials
NCT06132958
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 6, 2023
- Primary completion
- Jan 10, 2028
- Completion date
- Jan 10, 2028
- First posted
- Nov 15, 2023
- Last posted
- Dec 29, 2023
- Enrollment
- 710
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MerckLead sponsor
- MerckStudy director
- European Network for Gynaecological Oncological TrialCollaborator
- GOG Foundation, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.